|
1. Biologie
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
|
3. Prévention
|
|
|
Op-Ed Contributor: Why Is the Federal Government Afraid of Fat? [NY Times]
|
|
|
|
|
|
The
limit on total fat is an outdated concept, an obstacle to sensible
change that promotes harmful low-fat foods, undermines efforts to limit
refined grains and added sugars, and discourages the food industry from
developing products higher in healthy fats. Fortunately, the people
behind the Dietary Guidelines understand that. Will the government,
policy makers and the food industry take notice this time?
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
Why Women Shouldn't Cower To Concerns About Overdiagnosis Of Breast Cancer [Forbes]
|
|
|
|
|
|
I’ll
say up-front, one lesson from this unusual paper is how different
people including academics in non-medical fields, physicians and
patients, and journalists, advocates like me, can look at the same set
of facts and see, draw, frame or graph distinct conclusions, depending
on what they expect or want to find or prove and maybe learn or tell
others.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
Epizyme Extends Celgene Cancer Deal for $10M Upfront [Xconomy]
|
|
|
|
|
|
Celgene
has agreed to pay Epizyme $10 million upfront and as much as $610
million in milestones for the option to license three drug targets
Epizyme is developing, which use its method of inhibiting enzymes called
histone methyltransferases, or HMTs.
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.10 Politiques
|
|
|
|
|
6.11 Patients
|
|
|
|
6.6 Publications
|
|
|
The Metric Tide: Rethinking Research on Research [Wellcome Trust Blog]
|
|
|
|
|
|
The
call for more ‘science of science’ is therefore exciting and timely –
how might we make funding science more scientific? The question presents
an opportunity for sector-wide engagement and collaboration to bring
insight and efficiencies to how we fund research, what we should value
in different contexts, and what does and doesn’t work.
|
|
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.1 Bioinformatique
|
|
|
|
|
6.7.3 DMP
|
|
|
The Many Challenges But Promise of Big Data [Clinical Oncology News]
|
|
|
|
|
|
Flatiron
has several software products for oncology practices, including
OncoEMR, a cloud-based oncology-specific EHR for cancer clinics, and
OncoAnalytics, an EHR-agnostic analytics portal that administrators and
physicians can use to explore and analyze their practice data.
|
|
|
|
|
|